Financial Data and Key Metrics Changes - Fourth quarter sales reached $2.7 billion, representing a 7% increase year-over-year [18] - Core gross margin was 62.5%, down 50 basis points year-over-year, primarily due to incremental tariffs [20] - Core diluted earnings per share were $0.78 for the quarter [21] Business Line Data and Key Metrics Changes - Surgical franchise revenue increased by 6% year-over-year to $1.5 billion, with implantable sales at $474 million, up 2% [18] - Vision Care sales were $1.2 billion, up 7%, with contact lens sales increasing by 4% to $683 million [19] - Ocular Health sales reached $474 million, up 12%, driven by strong performance in the dry eye portfolio, including Tryptyr and Systane [19] Market Data and Key Metrics Changes - Global cataract procedural volumes grew approximately 3% in the fourth quarter [17] - The global contact lens market grew approximately 4%, primarily driven by strength in the U.S. market [17] Company Strategy and Development Direction - The company is focused on innovation, with multiple product launches expected to drive growth, including the Unity VCS and CS platforms [8][9] - The company aims to expand its IOL portfolio with new products like PanOptix Pro and TruPlus, enhancing its competitive position [10][11] - The company is committed to optimizing its cost structure and supporting long-term margin expansion through efficiency measures [24] Management's Comments on Operating Environment and Future Outlook - Management noted that while the markets showed improvement in the fourth quarter, they are not yet back to normal [32] - The outlook for 2026 assumes aggregate eye care market growth of 3%-4%, with top-line growth expected between 5% and 7% [22][23] - Management expressed confidence in sustaining a healthy double-digit growth rate in equipment sales due to strong demand for Unity products [39] Other Important Information - The company generated $1.7 billion of free cash flow in 2025, compared to $1.6 billion in 2024, enabling significant shareholder returns [21] - The board proposed a dividend of 28 Swiss centimes per share, aligning with the payout policy of approximately 10% of the previous year's core net income [25] Q&A Session Summary Question: Guidance visibility and market conditions - Management indicated that markets improved in the fourth quarter but are not yet back to normal, maintaining a balanced view for the upcoming year [32][33] Question: Equipment growth contribution from Unity - Unity significantly contributed to equipment growth, with strong demand and positive feedback from customers [39] Question: Tryptyr sales tracking and future expectations - Tryptyr is performing well, with management comfortable with peak sales estimates of $250 million to $400 million [41][42] Question: IOL market dynamics and growth expectations - The U.S. IOL market showed solid performance, with PanOptix Pro leading the way, while international markets faced more competition [52][54] Question: Surgeon capacity in the U.S. cataract market - Management noted that surgeon productivity is improving, with practices finding ways to increase surgery days [75][76] Question: Margin guidance and new product impact - Management expects continued price increases and leverage from new product launches to support margin improvement [78]

Financial Data and Key Metrics Changes - Fourth quarter sales reached $2.7 billion, representing a 7% increase year-over-year [18] - Core gross margin was 62.5%, down 50 basis points from the previous year, primarily due to incremental tariffs [20] - Core diluted earnings per share were $0.78 for the quarter [21] Business Line Data and Key Metrics Changes - Surgical franchise revenue increased by 6% year-over-year to $1.5 billion, with implantable sales at $474 million, up 2% [18] - Vision Care sales were $1.2 billion, up 7%, with contact lens sales increasing by 4% to $683 million [19] - Ocular Health sales reached $474 million, up 12%, driven by strong performance in the dry eye portfolio, including Tryptyr and Systane [20] Market Data and Key Metrics Changes - Global cataract procedural volumes grew approximately 3% in the fourth quarter [17] - The global contact lens market grew approximately 4%, primarily driven by strength in the U.S. market [17] Company Strategy and Development Direction - The company is focused on innovation, with multiple product launches expected to drive growth, including the Unity VCS and CS platforms [9][10] - The company aims to expand its IOL portfolio with new lenses like PanOptix Pro and TruPlus, enhancing its competitive position [11][12] - The company is committed to optimizing its cost structure and supporting long-term margin expansion through efficiency measures [24] Management's Comments on Operating Environment and Future Outlook - Management noted that while the markets showed improvement in the fourth quarter, they are not yet back to normal [32] - The company expects aggregate eye care markets to grow 3%-4% for the year, with top-line growth projected between 5% and 7% [22][23] - Management expressed confidence in sustaining a healthy double-digit growth rate in equipment as they enter 2026 [45] Other Important Information - The company generated $1.7 billion of free cash flow in 2025, compared to $1.6 billion in 2024, enabling significant shareholder returns [21] - The board proposed a dividend of 28 Swiss centimes per share, aligning with the payout policy of approximately 10% of the previous year's core net income [25] Q&A Session Summary Question: Guidance visibility and revenue growth expectations - Management indicated that the markets improved in the fourth quarter and expects a balanced view of market conditions for the upcoming year [32][34] Question: Contribution of Unity to equipment growth - Management confirmed that Unity significantly contributed to equipment growth, with strong demand and positive feedback from customers [38] Question: Tryptyr sales tracking and future expectations - Management expressed confidence in Tryptyr's performance, indicating it is tracking ahead of expectations and may reach the higher end of the previously stated peak sales range [41] Question: IOL market dynamics and future product launches - Management noted strong performance in the U.S. IOL market, with upcoming product launches expected to enhance competitive positioning [52][68] Question: U.S. surgeon capacity in the cataract market - Management highlighted that surgeon productivity is improving, with practices finding ways to increase surgery days and manage demand effectively [72][76] Question: Margin guidance and new product impact - Management indicated that new product launches and pricing will contribute positively to margins, alongside ongoing cost-saving initiatives [78]

Financial Data and Key Metrics Changes - Fourth quarter sales reached $2.7 billion, representing a 7% increase year-over-year [17] - Core gross margin for the fourth quarter was 62.5%, down 50 basis points from the previous year, primarily due to tariffs [19] - Core diluted earnings per share for the quarter were $0.78 [20] Business Line Data and Key Metrics Changes - Surgical franchise revenue increased by 6% year-over-year to $1.5 billion, with implantable sales at $474 million, up 2% [17] - Vision Care sales were $1.2 billion, up 7%, with contact lens sales increasing by 4% to $683 million [18] - Ocular Health sales reached $474 million, up 12%, driven by the dry eye portfolio, including Tryptyr and Systane [18] Market Data and Key Metrics Changes - Global cataract procedural volumes grew approximately 3% in the fourth quarter, with AT-IOL penetration increasing by 90 basis points [16] - The global contact lens market grew approximately 4%, primarily driven by the U.S. market [16] Company Strategy and Development Direction - The company is focused on innovation, with multiple product launches expected to drive growth, including the Unity VCS and CS platforms [5][6] - The company aims to expand its IOL portfolio with new products like PanOptix Pro and TruPlus, enhancing its competitive position [8][9] - The company is committed to operational improvements and cost structure optimization, targeting approximately $100 million in annualized run rate savings [24] Management's Comments on Operating Environment and Future Outlook - Management noted that while the full year results reflected softer markets, the second half of 2025 showed strength and momentum [5] - The outlook for 2026 anticipates top-line growth of 5% to 7%, reflecting a balanced view of market conditions and product launch progress [23] - Management expressed confidence in sustaining high-quality innovation and maintaining strong cash generation [27] Other Important Information - The company returned $848 million to shareholders in 2025, including $682 million in share repurchases and $166 million in dividends [20] - The company incurred $91 million in tariff-related charges in 2025, impacting gross margins [21] Q&A Session Summary Question: Guidance visibility and revenue expectations - Management indicated that while markets improved in Q4, they are not back to normal yet, maintaining a cautious outlook for 2026 [32][33] Question: Equipment growth contribution from Unity - Unity significantly contributed to equipment growth, with strong demand and positive feedback from surgeons [38][40] Question: Tryptyr sales tracking and future expectations - Tryptyr is performing well, with management confident in reaching peak sales estimates of $250 million to $400 million [42][43] Question: IOL market dynamics and competitive positioning - The U.S. IOL market showed solid performance, with PanOptix Pro gaining share, while international markets faced more competition [53][54] Question: Margin guidance and new product impact - Management expects continued price increases and leverage from new product launches to support margin improvements [81]

Core Insights - Alcon, Inc. reported fourth-quarter 2025 core earnings per share (EPS) of 78 cents, an increase of 8.3% year-over-year, but missed the Zacks Consensus Estimate by 0.76% [1] - The full-year core EPS for 2025 was $3.07, reflecting a 0.7% year-over-year increase and aligning with the Zacks Consensus Estimate [2] Revenue Performance - Alcon's net sales for the fourth quarter were $2.70 billion, slightly missing the Zacks Consensus Estimate by 0.2%, but showing a 9% increase year-over-year (7% at constant exchange rates) [3] - For the full year 2025, net sales totaled $10.32 billion, up 4.9% year-over-year, matching the Zacks Consensus Estimate [3] Segment Analysis - Surgical segment sales reached $1.5 billion, up 9% year-over-year (6% at constant exchange rates), with notable growth in Implantables and Equipment/Other categories [5] - Vision Care segment reported total sales of $4.60 billion, a 6% year-over-year increase (5% at constant exchange rates), driven by innovations in Contact Lenses and Ocular Health products [6] Margin and Cost Analysis - The cost of net sales in Q4 was $1.20 billion, up 8.8% year-over-year, while gross profit increased by 9.3% to $1.51 billion, resulting in a gross margin expansion of 12 basis points to 56% [7] - SG&A expenses rose by 12.3% year-over-year, and R&D expenses increased by 17.7%, leading to a contraction of the operating margin by 158 basis points to 12.5% [7] Future Outlook - Alcon projects 2026 sales growth of 5%-7% and core EPS growth of 9%-12%, with the Zacks Consensus Estimate for 2026 earnings at $3.37 per share, indicating a 9.7% improvement [10] - The company launched several innovative products throughout 2025, contributing to sales acceleration and a balanced outlook for 2026 [12] Financial Position - At the end of Q4 2025, Alcon had cash and cash equivalents of $1.53 billion, down from $1.68 billion at the end of 2024, while cumulative net cash flow from operating activities increased to $2.27 billion [9]

Fourth-Quarter and Full-Year 2025 Results February 24, 2026 1 Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "bel ...

Alcon (NYSE: ALC) FY Conference Summary Company Overview - Alcon is an eye care company focused on addressing significant vision-related concerns, particularly among the elderly, such as refractive errors, presbyopia, and dry eye [2][3] - The company invests approximately $1 billion annually in developing eye care programs and products [3] Surgical Business Insights - The surgical market remains solid, with expectations of continued growth driven by an aging population and increasing demand for cataract surgeries [4] - Historically, the market has grown at a rate of 4% to 5% [4] - Alcon has a diverse portfolio of products for cataract surgery, including innovations in intraocular lenses (IOLs) and phacoemulsification machines [5] - The company plans to launch 10 to 15 new products in the coming years, enhancing its market presence [5] Unity Platform and Efficiency - The Unity platform aims to improve efficiency in cataract surgery by integrating diagnostic data into a cloud planner, enhancing procedural planning and outcomes [6][7] - The Unity VCS phacoemulsification machine has shown significant efficiency gains, allowing surgeons to perform more surgeries per day [8][9] - Bench tests indicate that the Unity 4D phaco machine is 48% faster than traditional methods, with reduced energy delivery to the eye [10][11] Product Innovations - The PanOptix IOL has been successful, with an upgraded version launched to improve light utilization and reduce glare and halos [12] - New product launches include the TruePlus monofocal lenses, which enhance intermediate vision without compromising distance vision [13] - The vision care segment is stable, with expected market growth of 4% to 6% [14] Vision Care and Pharmaceuticals - Alcon's TripTier product, a novel dry eye treatment, has received positive feedback and is expected to gain reimbursement support [19][36] - The company is expanding its contact lens offerings and has seen strong growth in the preservative-free eye drop market, which is growing at 20% [17][18] Market Dynamics and Competitive Landscape - The IOL market is competitive, with new entrants and pricing pressures expected [33][34] - Alcon aims to maintain its premium pricing by emphasizing the quality and effectiveness of its products [35] Financial Performance and Projections - Alcon generates approximately $2 billion in free cash flow annually, which can be used for various strategic initiatives [23][45] - The company anticipates margin expansion of 150 to 200 basis points, despite some pressure from investments and tariffs [42][43] Strategic Outlook - Alcon remains focused on organic growth and innovation, with a disciplined approach to potential M&A opportunities [46][50] - The company is cautious about market guidance, acknowledging the unusual conditions of the previous year but maintaining a long-term growth outlook [51] Additional Considerations - Alcon is not currently interested in entering the pharmaceutical space for presbyopia treatments due to concerns about side effects [52] - The trend of private equity acquiring ophthalmology practices has slowed, with challenges in achieving desired economic efficiencies [53][54] This summary encapsulates the key points from Alcon's FY Conference, highlighting the company's strategic focus, market dynamics, and product innovations in the eye care industry.

J.P. Morgan Healthcare Conference David J. Endicott Chief Executive Officer January 13th, 2026 Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," ...

Core Insights - Alcon, Inc. reported third-quarter 2025 core earnings per share (EPS) of 79 cents, a decrease of 2.5% year-over-year, but exceeded the Zacks Consensus Estimate by 2.6% [1] - The company's net sales for the quarter were $2.59 billion, reflecting a 6.4% increase from the previous year, although it slightly missed consensus expectations [2] - Alcon maintained its 2025 financial guidance, projecting net sales between $10.30 billion and $10.40 billion, indicating a year-over-year growth of 4-5% at constant exchange rates [9] Revenue Breakdown - Alcon operates through two segments: Surgical and Vision Care [3] - Surgical sales reached $1.40 billion, up 6% year-over-year, with notable growth in Equipment/Other sales, which increased by 13% at constant exchange rates [4] - Vision Care segment reported total sales of $1.20 billion, a 7% increase year-over-year, driven by product innovation in Contact Lenses and Ocular Health [5] Margin Performance - The cost of net sales was $1.14 billion, up 6.8% year-over-year, while gross profit rose 6.1% to $1.45 billion, leading to a slight contraction in gross margin to 56.1% [6] - Selling, General and Administrative (SG&A) expenses increased by 6.9%, and Research and Development (R&D) expenses rose by 11.1%, resulting in an operating margin contraction of 71 basis points to 13% [6] Financial Position - Alcon ended the third quarter with cash and cash equivalents of $1.50 billion, an increase from $1.41 billion at the end of the previous quarter [8] - Cumulative net cash flow from operating activities was $1.61 billion, slightly down from $1.62 billion in the year-ago period, while free cash flow totaled $1.20 billion compared to $1.3 billion a year ago [8] Product Launches and Acquisitions - Alcon is experiencing early demand for new products like Unity VCS and PanOptix Pro, which are expected to drive future growth [12] - The company announced a merger agreement to acquire STAAR Surgical, enhancing its presence in myopia correction, and completed the acquisition of LumiThera, adding the Valeda PBM device to its portfolio [13]

Financial Performance Highlights - Third-quarter net sales reached $2.6 billion, a 6% increase year-over-year on a reported basis and a 5% increase in constant currency[16] - Third-quarter core diluted EPS was $0.79[12] - The company's free cash flow for the first nine months of the year was $1.2 billion[15] Segment Performance - Surgical net sales in the third quarter were $1.42 billion, up 6% on a reported basis and 5% in constant currency[23] - Vision Care net sales in the third quarter were $1.169 billion, up 6% on a reported basis and 5% in constant currency[24] - For the first nine months of 2025, Vision Care accounted for 45% ($3.4 billion) and Surgical accounted for 55% ($4.2 billion) of the company's $7.6 billion in sales[22] Profitability Metrics - Third-quarter IFRS operating margin was 12.8%, a decrease of 80 basis points year-over-year[16] - Third-quarter core operating margin was 20.2%, a decrease of 40 basis points year-over-year[14] - For the first nine months of 2025, the IFRS operating margin was 13.7%[32] - For the first nine months of 2025, the core operating margin was 20.0%[45] Outlook - The company maintained its full-year 2025 net sales outlook of $10.3 to $10.4 billion, representing a 4% to 5% increase in constant currency[57] - The company maintained its full-year 2025 core diluted EPS outlook of $3.05 to $3.15, representing a 0% to +2% increase in constant currency[57]